# Premarket Notification 510(k) Summary

Assigned 510(k) Number: K070458

Submitted by : Name: Contact Person:

Address:

Biomedical Diagnostics S.A (bmd)   
Christelle COURIVAUD   
Regulatory Affairs Manager   
Actipole 25, 4-6 Bld de Beaubourg   
77435 Marne-La-Vallée Cedex 2   
FRANCE   
33 (0)1 64 62 10 12   
33 (0)1 64 62 09 66   
2002026252   
Telephone:   
Fax:   
Establishment   
Registration Number:

US Agent correspondent:

Hoppe Regulatory Consultants   
Ms P. Ann HOPPE   
2335 Massey Lane   
Decatur GA 30033 USA   
Phone: 404 920 1847   
E-mail: HoppeRegulatory@cs.com

# Device Name

Trade/Proprietary Name :

# FIDISTM VASCULITIS Assay kit

Common/Usual Name :

MX007 - FIDISTM VASCULITIS: DetectiOn test for autoantibodies directed against Myeloperoxidase (MPO), Serine Proteinase 3 (PR3) and Glomerular Basement Membrane (GBM) in human serum

# Classification Names:

Test system, Antineutrophil Cytoplasmic Antibodies (ANCA) Devices, Measure, Antibodies to Glomerular Basement Membrane (GBM)

Trade/Proprietary Name : Classification Name:

FIDISTM Analyzer Instrumentation for Chemical Multiplex Systems

Trade/Proprietary Name : Classification Name:

CARISTM System Device, Microtiter diluting/Dispensing

# Intended use

The FIDIS™ VASCULITIS\* kit is a semi-quantitative homogeneous fluorescent-based microparticle immunoassay using flow cytometry. The test system is used to simultaneously detect the presence of anti-neutrophil cytoplasmic antibodies (ANCA) directed against Myeloperoxidase $( M P O )$ , Serine Proteinase 3 (PR3) and antibodies directed against glomerular basement membrane (GBM) in human serum samples.

The results of the FIDIS™ VASCULITIS\* test are to be used in conjunction with the clinical findings and the other laboratory tests to aid in the diagnosis of various primary systemic small blood vessel vasculitides and glomerular basement membrane disease.

# Clinical utility:

The detection of ANCA is associated with primary systemic small blood vessel vasculitides: Wegener's granulomatosis, Churg Strauss syndromes, microscopic periarteritis and idiopathic crescentic glomerulonephritis; and the detection of anti-GBM antibodies is associated with Goodpasture's syndrome.

FIDIS™ VASCULITIS\* kit uses serum only, and is to be run on the FIDIS™ Instrument and MLX-BOOSTER Software.

FIDIS™ VASCULITIS\* kit may be used with the CARIS™ system (diluting and dispensing device).

This test is for In vitro diagnostic use.

\* Detection of the serologic markers for primary systemic small blood vessel vasculitides (ANCA) and for Goodpasture syndrome (GBM).

# Materials supplied

<table><tr><td colspan="1" rowspan="1">1 x 96 wells microplate including a filtering membrane and a lid.</td><td colspan="1" rowspan="1">1 plate</td></tr><tr><td colspan="1" rowspan="1">1 vial (A) of 3 sets of color-coded microsphere beads coupled withMPO, PR3 and GBM*, plus 1 set of internal standard beads.Ready to use</td><td colspan="1" rowspan="1">1 x 6mL</td></tr><tr><td colspan="1" rowspan="1">1 vial (B) of sample dilution buffer (PBS-Tween) (white vial)Ready to use</td><td colspan="1" rowspan="1">2 x 115mL</td></tr><tr><td colspan="1" rowspan="1">1 vial of calibrator** titered for the specificities to be measured.Ready to useEach titer is printed on the vial label</td><td colspan="1" rowspan="1">1 x 1,5mL</td></tr><tr><td colspan="1" rowspan="1">1 vial of positive control** concentrate. This control has a standardreactivity that provides evidence of the proper functioning ofreagents and correct assay performance.To be dilutedExpected values are printed on the vial label.</td><td colspan="1" rowspan="1">1 x 250 μL</td></tr><tr><td colspan="1" rowspan="1">1 vial of negative control** concentrate. To be diluted</td><td colspan="1" rowspan="1">1 x 250μL</td></tr><tr><td colspan="1" rowspan="1">1 vial of anti-human IgG coupled to phycoerythrinReady to use</td><td colspan="1" rowspan="1">1 x 12mL</td></tr><tr><td colspan="1" rowspan="1">1 vial (C) of washing buffer (PBS-Tween) (black vial)Ready to use</td><td colspan="1" rowspan="1">1 x 100mL</td></tr><tr><td colspan="1" rowspan="1">Package Insert</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Microplate Assay Configuration Worksheet</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Microplate sealing films</td><td colspan="1" rowspan="1">6</td></tr></table>

\* GBM antigen purified from type IV collagen. \*\* Calibrator and control titers are expressed in arbitrary units per mL (AU/mL).

# Predicate Device

<table><tr><td rowspan=1 colspan=1>510K Number</td><td rowspan=1 colspan=1>Device Classification Name</td><td rowspan=1 colspan=1>Manufacturer Name</td></tr><tr><td rowspan=1 colspan=1>K053012</td><td rowspan=1 colspan=1>FIDISTM VASCULITIS</td><td rowspan=1 colspan=1>Biomedical DiagnosticsS.A.(bmd)</td></tr></table>

# Comparison with the predicate

<table><tr><td>Predicate Device Modified Device FIDISTVASCULITIS 4K053012 FIDISIMVASCULITIS</td></tr></table>

<table><tr><td colspan="2" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Individual determination in humanserum, of IgG antibodies against:MPO, PR3 and GBM</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="2" rowspan="1">Antigen</td><td colspan="1" rowspan="1">-  MPO: purified antigenPR3: purified antigenGBM: purified antigen</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="3">CO-EE</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">&lt;20 AU/mLfor the 3 specificities</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Equivocal</td><td colspan="1" rowspan="1">20-25 AU/mLfor the 3 specificities</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">&gt;25 AU/mLfor the 3 specificities</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="2" rowspan="1">Material supplied</td><td colspan="1" rowspan="1">Microplate with caps</td><td colspan="1" rowspan="1">Microplate with sealing films (no changein function and provides flexible use)</td></tr><tr><td colspan="2" rowspan="1">Sample dilution</td><td colspan="1" rowspan="1">PBS-Tween concentrated</td><td colspan="1" rowspan="1">Sample dilution buffer - sameingredients but ready to use</td></tr><tr><td colspan="2" rowspan="1">Wash buffer</td><td colspan="1" rowspan="1">PBS-Tween concentrated</td><td colspan="1" rowspan="1">Washing buffer - same ingredients butready to use</td></tr><tr><td colspan="1" rowspan="1">Internal standard beads</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="3">Assay configuration</td><td colspan="1" rowspan="1">1 "reagent-blank" well1 "calibrator" well1 "negative control" wellI "positive control" well</td><td colspan="1" rowspan="1">1 "reagent-blank" well1 "negative control" well1 "positive control" well2 "calibrator" wells</td></tr><tr><td colspan="1" rowspan="1">Diluted sample wells</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">A second calibrator well every 32 wellseries</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Incubation time</td><td colspan="1" rowspan="1">2 x 30mn RT</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay protocol</td><td colspan="1" rowspan="1">Optional final wash step</td><td colspan="1" rowspan="1">Final wash step (not optional)</td></tr><tr><td colspan="1" rowspan="1">Software</td><td colspan="1" rowspan="1">MLX-Booster Version 1.35</td><td colspan="1" rowspan="1">MLX-Booster Version 2.2</td></tr><tr><td colspan="1" rowspan="1">Assay technology</td><td colspan="1" rowspan="1">Flow cytometric</td><td colspan="1" rowspan="1">Flow cytometric</td></tr><tr><td colspan="1" rowspan="1">Sample delivery</td><td colspan="1" rowspan="1">Manual pipetting</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Automated sample delivery(option)</td><td colspan="1" rowspan="1">CARISTM (pipettor)</td><td colspan="1" rowspan="1">Same</td></tr></table>

# Performance Characteristics

# Analytical performance

# a. Precision

Precision of the assay was assessed in 16 samples for antibodies to each of the three analytes (MPO, PR3, GBM) and 3 negative samples. Precision was determined by calculating the within-run (intra-assay) and the between run (interassay).

For within-run: 10 tests in a same run.   
For between-run: 5 runs, 3 tests per run.

Table 1: Summary of FIDISTM Vasculitis precision results   

<table><tr><td rowspan=3 colspan=1>ample</td><td rowspan=3 colspan=1>Acceptancecriteria forwithmn-ruandbetween-run</td><td rowspan=1 colspan=1>MPO-PR3 and GBM paramete</td></tr><tr><td rowspan=1 colspan=1>Beween-rum </td></tr><tr><td rowspan=1 colspan=1>Mmimal%cy Maximal Z.cv</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Less than10 AU/mL</td><td rowspan=1 colspan=1>Not calulated</td><td rowspan=1 colspan=1>Not calculated</td><td rowspan=1 colspan=1>Not calculated</td><td rowspan=1 colspan=1>Not calculated</td><td rowspan=1 colspan=1>Not calculated</td></tr><tr><td rowspan=1 colspan=1>10 to 19AU/mL</td><td rowspan=1 colspan=1>%CV≤20%</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>11.3%</td><td rowspan=1 colspan=1>11.2%</td><td rowspan=1 colspan=1>19.6%</td></tr><tr><td rowspan=1 colspan=1>20 to 400AU/mL</td><td rowspan=1 colspan=1>%CV≤15%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>12.4%</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>14.2%</td></tr></table>

# b. Linearity/ assay reportable range

FIDIS™ VASCULITIS assay has been optimized to express the average binding capacity at the current dilution (1:200) by a flow cytometric reading determined as the median fluorescence value obtained from 200 microspheres per parameter.

Further dilution potentially gives rise to inaccurate results because the reaction conditions and the equilibrium of the immunological reaction may be modified.

# c. Interfering Substances

The study was conducted by testing 27 MPO, PR3, GBM negative samples characterized as positive for various potential interferences obtained from a routine laboratory.

![](images/7d5dba6a20c07c2f928eaea8a047f96bf3f4e2b422d84609cbc0f0be45b383f0.jpg)  
N: number of samples tested

# d. Threshold values

Threshold values were estimated from the 2 selected populations:

37 samples from blood donors   
28 samples selected for their potential biological interferences

The negative thresholds $( 2 0 \mathbf { A } \mathbb { U } / \mathbf { m } \mathbf { L } )$ correspond to the $1 0 0 \%$ of negative MPO/GBM samples and $9 8 . 5 \%$ of negative PR3 samples for the populations studied.

# e.Stability of the assay results after final wash step

This assay included 3 test series for 6 samples per analyte (MPO, PR3, GBM). Each series of tests was washed and read after different times:

EY ${ \bf T } = { \bf 0 }$ hour: the first series of tests was read immediately after the final wash step.   
EPY $\mathrm { \bf T } = { \bf 4 }$ hours: the second series of test was read after 4 hours of storage at room temperature away from direct sunlight.

T=18 hours: the last series was read after 18 hours of storage at room temperature away from direct sunlight.

Table 3: Summary of Stability of the assay results after final wash step   

<table><tr><td rowspan=1 colspan=1>%CV acceptancecritera</td><td rowspan=1 colspan=1>Parameter.</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>MeanA(AU/mL)6</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=18 colspan=1>CV%&lt;15%</td><td rowspan=6 colspan=1>MPO</td><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>14%</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>6%</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>4%</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>4%</td></tr><tr><td rowspan=1 colspan=1>Sample 5</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>12%</td></tr><tr><td rowspan=1 colspan=1>Sample 6</td><td rowspan=1 colspan=1>260</td><td rowspan=1 colspan=1>8%</td></tr><tr><td rowspan=6 colspan=1>PR3</td><td rowspan=1 colspan=1>Sample 7</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>11%</td></tr><tr><td rowspan=1 colspan=1>Sample 8</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>3%</td></tr><tr><td rowspan=1 colspan=1>Sample 9</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>3%</td></tr><tr><td rowspan=1 colspan=1>Sample 10</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>10%</td></tr><tr><td rowspan=1 colspan=1>Sample 11</td><td rowspan=1 colspan=1>231</td><td rowspan=1 colspan=1>8%</td></tr><tr><td rowspan=1 colspan=1>Sample 12</td><td rowspan=1 colspan=1>834</td><td rowspan=1 colspan=1>6%</td></tr><tr><td rowspan=6 colspan=1>GBM</td><td rowspan=1 colspan=1>Sample 13</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>5%</td></tr><tr><td rowspan=1 colspan=1>Sample 14</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>5%</td></tr><tr><td rowspan=1 colspan=1>Sample 15</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>6%</td></tr><tr><td rowspan=1 colspan=1>Sample 16</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>5%</td></tr><tr><td rowspan=1 colspan=1>Sample 17</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>7%</td></tr><tr><td rowspan=1 colspan=1>Sample 18</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>5%</td></tr></table>

- Based on the common laboratories practices, the time range recommended is one hour for a plate when stored at room temperature away from direct sunlh"

# 2Comparison study with predicate

bmd has compared the results obtained with modified FIDISTM VASCULITIS versus the results obtained with predicate FIDISTM VASCULITIS K053012.

The study was performed on 219 samples characterized with the predicate test and the result repartition is described below:

135 samples were positive for one or more parameters ANCA and/or GBM.   
84 negative samples including some samples evaluated for their potential biological interferences.

All equivocal samples with predicate and FIDIS™ VASCULITIS tests are considered negative for the comparison and the evaluation studies.

# Table 4: MPO performances

<table><tr><td rowspan=1 colspan=2>MPO</td><td rowspan=1 colspan=3>PREDICATE FIDIS™VASCULITISK053012Positive Negative  Total</td></tr><tr><td rowspan=3 colspan=2>MODIFIED        PositiveFIDIS™        NegativeVASCULITIS       Total</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>219</td></tr></table>

# $\Rightarrow$ Table 5: PR3 performances

<table><tr><td rowspan=2 colspan=2>PR3</td><td rowspan=2 colspan=3>PREDICATE FIDISTVASCULITISK053012Positive Negative   Total</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=2>MODIFIED      PositiveFIDISTM      NegativeVASCULITIS     Total</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>48</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>171</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>219</td></tr></table>

# $\Rightarrow$ Table 6: GBM performances

There were 7 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: E $9 7 . 1 8 \%$ (69/71)   
Negative percent agreement: $1 0 0 \%$ (148/148)   
Overall agreement: $9 9 . 0 9 \%$ (217/219)

There were 11 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Table 7: Summary of performance agreement results   

<table><tr><td rowspan=2 colspan=1>GBM</td><td rowspan=2 colspan=3>PREDICATE FIDiSVASCULITISK053012Positive  Negative   Total</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>MODIFIED     PositiveFIDIS™     Negative</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>194</td></tr><tr><td rowspan=1 colspan=1>VASCULITIS    Total</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>219</td></tr></table>

Positive percent agreement: EY $9 5 . 9 2 \%$ (47/49)   
Negative percent agreement: $9 9 . 4 1 \%$ (169/170)   
Overall agreement: $9 8 . 6 3 \%$ (216/219)

There were 3 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $1 0 0 \%$ (25/25)   
Negative percent agreement: $1 0 0 \%$ (194/194)   
Overall agreement: $100 \%$ (219/219)

![](images/b503b0d4caa9e00f02c6e9d1a35e7cc80463db5b4241280f310eb7a486c2be27.jpg)

<table><tr><td rowspan=1 colspan=1>MPO</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>97.18%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>99.09%</td></tr><tr><td rowspan=1 colspan=1>PR3</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>95.92%</td><td rowspan=1 colspan=1>99.41%</td><td rowspan=1 colspan=1>98.63%</td></tr><tr><td rowspan=1 colspan=1>GBM</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

In addition to the analysis above, the $9 5 \%$ one-sided lower confidence limit in percent of proportion agreement $9 5 \%$ LCL $( \% )$ was calculated using the Exact Binomial Test for proportions to determine how low this proportion could be with a $9 5 \%$ confidence.

Table 7a: Summary of performance agreements results - $95 \%$ LCL $( \% )$   

<table><tr><td rowspan=2 colspan=1>AntigenicSecificity</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=4>Positive Agreement</td><td rowspan=1 colspan=4>Negative Agreement</td><td rowspan=1 colspan=4>Overall Agreement</td></tr><tr><td rowspan=1 colspan=1>N{</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>$(r))$</td><td rowspan=1 colspan=1>95%LCL(%)</td><td rowspan=1 colspan=1>N{2</td><td rowspan=1 colspan=1>R_</td><td rowspan=1 colspan=1>$P_2</td><td rowspan=1 colspan=1>95%LCL(%)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>P(%)</td><td rowspan=1 colspan=1>95%LCL(%)</td></tr><tr><td rowspan=1 colspan=1>MPO</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>97.18</td><td rowspan=1 colspan=1>91.40</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>98.00</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>217</td><td rowspan=1 colspan=1>99.09</td><td rowspan=1 colspan=1>97.15</td></tr><tr><td rowspan=1 colspan=1>PR3</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>95.92</td><td rowspan=1 colspan=1>87.70</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>99.41</td><td rowspan=1 colspan=1>97.24</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>98.63</td><td rowspan=1 colspan=1>96.50</td></tr><tr><td rowspan=1 colspan=1>GBM</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>88.71</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>98.47</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>98.64</td></tr></table>

EPY $\mathbf { N _ { 1 } } = \mathbf { N _ { 0 } }$ of positives; ${ \bf R } _ { 1 } = { \bf N } _ { 0 }$ of positive agreements; $\mathbb { P } _ { 1 } = \mathbb { R } _ { 1 } / \mathbb { N } _ { 1 }$ EY ${ \bf N } _ { 2 } = { \bf N } _ { 0 }$ of negatives; ${ \bf R } _ { 2 } = { \bf N } { \bf 0 } .$ of negative agreements; ${ \bf P } _ { 2 } = { \bf R } _ { 2 } / { \bf N } _ { 2 }$ EY $\Nu = \Nu _ { 1 } + \Nu _ { 2 }$ ${ \bf R } = { \bf R } _ { 1 } + { \bf R } _ { 2 }$ . ${ \bf P } = { \bf R } / { \bf N }$

All of results show that FIDISTM VASCULITIS system can be considered substantially equivalent to the predicate K053012 FIDISTM VASCULITIS system.

3. Performance data for modified FIDISTM VASCULITIS with CARISTM (diluting/ dispensing Device)

# a. Precision

Internal study was conducted to evaluate the reproducibility of the use of CARISTM with modified FIDISTM VASCULITIS.

Precision of the assay was assessed in 16 samples for antibodies to each of the three parameters (MPO, PR3, GBM) and 3 negative samples. Precision was determined by calculating the within-run (intra-assay) and the between-run (interassay).

Precision was determined by calculating the within-run (intra-assay) and the between-run (inter-assay).

For within-run: 10 times in a same run.   
For between-run: 5 runs, 3 times per run.

Table 8: Summary of CARISTM precision results   

<table><tr><td rowspan=1 colspan=1>Sample range</td><td rowspan=1 colspan=1>Acceptancecriteria forwithin-runand between-run</td><td rowspan=1 colspan=1>Within-runminimal CV%for MPO, PR3and GBMparameters</td><td rowspan=1 colspan=1>Within-runmaximalCV% forMPO, PR3and GBMparameters</td><td rowspan=1 colspan=1>Between-runminimal CV%for MPO, PR3and GBMparameters</td><td rowspan=1 colspan=1>Between-runmaximalCV% forMPO, PR3and GBMparameters</td></tr><tr><td rowspan=1 colspan=1>Less than10AU/mL</td><td rowspan=1 colspan=1>Not calculated</td><td rowspan=1 colspan=1>Not calculated</td><td rowspan=1 colspan=1>Not calculated</td><td rowspan=1 colspan=1>Not calculated</td><td rowspan=1 colspan=1>Not calculated</td></tr><tr><td rowspan=1 colspan=1>10 to 19AU/mL</td><td rowspan=1 colspan=1>CV=20%</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>13.6%</td></tr><tr><td rowspan=1 colspan=1>20 to 400AU/mL</td><td rowspan=1 colspan=1>CV=15%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>10.8%</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>11.7%</td></tr></table>

# b. Comparison studies (manual versus automated assay preparation steps)

bmd has compared the results obtained with modified FIDISTM VASCULITIS for manual or automated (with CARISTM).assay preparation steps.

The study was performed on 117 samples characterized with the modified FIDISTM VASCULITIS with manual assay preparation step.

The result repartition is described below:

75 positive samples for one or more parameters ANCA and/or GBM. 42 negative samples including some samples evaluated for their potential biological interferences.

All equivocal samples are considered negative for the comparison and the evaluation studies.

<table><tr><td rowspan=2 colspan=2>MPO</td><td rowspan=2 colspan=3>MODIFiED FIDISTVASCULITISManualPositiveNegative   Total</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=2>MODIFIED     PositiveFIDISTMVASCULITIS Negative</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>81</td></tr><tr><td rowspan=1 colspan=1>With CARIS</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>117</td></tr></table>

# $\Rightarrow$ Table 10: PR3 performances

<table><tr><td rowspan=2 colspan=1>PR3</td><td rowspan=2 colspan=3>MODIFIED FIDISTVASCULITISManualPositive Negative   Total</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>MODIFIED     PositiveFIDISTMVASCULITIS Negative</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>90</td></tr><tr><td rowspan=1 colspan=1>With CARIS     Total</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>117</td></tr></table>

# Table 11: GBM performances

There were 5 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $1 0 0 \%$   
(34/34)   
Negative percent agreement:   
EMP $9 7 . 5 9 \%$ (81/83)   
Overall agreement: $9 8 . 2 9 \%$   
(115/117)

There were 6 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

<table><tr><td rowspan=2 colspan=2>GBMH</td><td rowspan=2 colspan=3>MODIFIED FIDISTVASCULITISManualPositiveNegative   Total</td></tr><tr><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=2>MODIFIED     PositiveFIDISTMVASCULITIS NegativeWith CARIS     Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>94</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>117</td></tr></table>

There were 3 equivocal results with the assay. For purposes of calculation, these results were considered as negative.

Positive percent agreement: $100 \%$ (23/23)   
Negative percent agreement: $1 0 0 \%$ (94/94)   
Overall agreement: $1 0 0 \%$ (117/117)

Table 12: Summary of performance agreements results obtained with CARISTM versus manual   

<table><tr><td rowspan=1 colspan=1>AntigenicSpecificity</td><td rowspan=1 colspan=1>Samplenumber</td><td rowspan=1 colspan=1>Positivepercentagreement</td><td rowspan=1 colspan=1>Negativepercentagreement</td><td rowspan=1 colspan=1>Overallagreement</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>proportion</td><td rowspan=1 colspan=1>proportion</td><td rowspan=1 colspan=1>proportion</td></tr><tr><td rowspan=1 colspan=1>MPO</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.59%</td><td rowspan=1 colspan=1>98.29%</td></tr><tr><td rowspan=1 colspan=1>PR3</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.83%</td><td rowspan=1 colspan=1>98.29%</td></tr><tr><td rowspan=1 colspan=1>GBM</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

In addition to the analysis above, the $9 5 \%$ one-sided lower confidence limit in percent of proportion agreement $9 5 \%$ LCL $( \% )$ was calculated using the Exact Binomial Test for proportions to determine how low this proportion could be with a $9 5 \%$ confidence.

Table 12a: Summary of performance agreements results obtained with CARISTM versus manual . $95 \%$ LCL $( \% )$   

<table><tr><td rowspan=2 colspan=1>AntigenicSpecificity</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=4>Positive Agreement</td><td rowspan=1 colspan=4>Negative Agreement</td><td rowspan=1 colspan=4>Overall Agreement</td></tr><tr><td rowspan=1 colspan=1>N1</td><td rowspan=1 colspan=1>R1</td><td rowspan=1 colspan=1>P1 (%)</td><td rowspan=1 colspan=1>95%LCL(%)</td><td rowspan=1 colspan=1>N_2</td><td rowspan=1 colspan=1>R2</td><td rowspan=1 colspan=1>P_2 (%)</td><td rowspan=1 colspan=1>95%LCL(%)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>P(%)</td><td rowspan=1 colspan=1>95%LCL(%)</td></tr><tr><td rowspan=1 colspan=1>MPO</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>91.57</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>97.59</td><td rowspan=1 colspan=1>92.61</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>98.29</td><td rowspan=1 colspan=1>94.72</td></tr><tr><td rowspan=1 colspan=1>PR3</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>88.71</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>97.83</td><td rowspan=1 colspan=1>93.31</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>98.29</td><td rowspan=1 colspan=1>94.72</td></tr><tr><td rowspan=1 colspan=1>GBM</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>87.79</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>96.86</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>97.47</td></tr></table>

EPY ${ \bf N } _ { 1 } = { \bf N } _ { 0 }$ of positives; ${ \bf R } _ { 1 } = { \bf N } _ { 0 }$ of positive agreements; $\mathbf { P } _ { 1 } = \mathbf { R } _ { 1 } / \mathbf { N } _ { 1 }$ EY E ${ \bf N } _ { 2 } = { \bf N } _ { 0 }$ of negatives; EPY ${ \bf R } _ { 2 } = { \bf N } { \bf o }$ of negative agreements; ${ \bf P } _ { 2 } = { \bf R } _ { 2 } / { \bf N } _ { 2 }$ ${ \aleph } = { \aleph } _ { 1 } + { \aleph } _ { 2 }$ .y ${ \mathbb R } = { \mathbb R } _ { 1 } + { \mathbb R } _ { 2 }$ ${ \bf P } = { \bf R } / { \bf N }$

All of previous evaluation results indicate that manual and automated (with CARISTM) assay preparation steps are substantially equivalent.

# Conclusions

In conclusion, all supporting data demonstrate that the FIDIS™ VASCULITIS system can be considered substantially equivalent to the predicate device.

# DEC 2 1 2007

Biomedical Diagnostics S.A. (BMD)   
c/o Ms. Christelle Courivaud   
Regulatory Affairs Manager   
Actipole 25,   
4-6 Bld de Beaubourg   
77435 Marne La Vallée cedex 2   
France

Re: k070458 Trade/Device Name: FIDIS™M VASCULITIS\* Assay Regulation Number: 21 CFR 866.5660 Regulation Name: Multiple autoantibodies innmunological test system Regulatory Class: Class II Product Code: MOB, MVJ Dated: November 27, 2007 Received: November 30, 2007

Dear Ms. Courivaud:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to

Page 2 -

begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/964f45d44b2e5d251828c93fbdfb86071ea111bc9c6d54ebb5eb355303a0737e.jpg)

Robert L. Becker, Jr., M.D., Ph.D.   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known): K070458

Device Name: FIDISTM VASCULITIS\*

# Indication For Use:

The FIDIS™ VASCULITIS\* kit is a semi-quantitative homogeneous fluorescent-based microparticle immunoassay using flow cytometry. The test system is used to simultaneously detect the presence of anti-neutrophil cytoplasmic antibodies (ANCA) directed against Myeloperoxidase $( M P O )$ , Serine Proteinase 3 (PR3) and antibodies directed against glomerular basement membrane (GBM) in human serum samples.

The results of the FIDIS™ VASCULITIS\* test are to be used in conjunction with the clinical findings and the other laboratory tests to aid in the diagnosis of various primary systemic small blood vessel vasculitides and glomerular basement membrane disease.

# Clinical utility:

The detection of ANCA is associated with primary systemic small blood vessel vasculitides: Wegener's granulomatosis, Churg Strauss syndromes, microscopic periarteritis and idiopathic crescentic glomerulonephritis; and the detection. of anti-GBM antibodies is associated with Goodpasture's syndrome.

FIDIS™ VASCULITIS\* kit uses serum only, and is to be run on the FIDIS™ Instrument and MLX-BOOSTER Software.

FIDIS™ VASCULITIS\* kit may be used with the CARIS™ system (diluting and dispensing device).

This test is for In vitro Diagnostic Use.

\*Detection of the serologic markers for primary systemic small blood vessel vasculitides (ANCA) and for Goodpasture syndrome (GBM).

And/Or

Prescription Use_X (21 CFR Part 801 Subpart D)

Over the Counter Use (21 CFR Part 801 Subpart C)